137 related articles for article (PubMed ID: 29349823)
21. Dietary cadmium intake and risk of breast, endometrial and ovarian cancer in Danish postmenopausal women: a prospective cohort study.
Eriksen KT; Halkjær J; Sørensen M; Meliker JR; McElroy JA; Tjønneland A; Raaschou-Nielsen O
PLoS One; 2014; 9(6):e100815. PubMed ID: 24963789
[TBL] [Abstract][Full Text] [Related]
22. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer.
Dimitrakakis C; Keramopoulos D; Vourli G; Gaki V; Bredakis N; Keramopoulos A
Climacteric; 2005 Dec; 8(4):342-51. PubMed ID: 16390769
[TBL] [Abstract][Full Text] [Related]
23. The safety of tibolone in epithelial ovarian cancer patients.
Lee KB; Lee JM; Yoon JH; Park CY
Maturitas; 2006 Sep; 55(2):156-61. PubMed ID: 16563669
[TBL] [Abstract][Full Text] [Related]
24. Postmenopausal hormone therapy and the risk of breast cancer in Norway.
Román M; Sakshaug S; Graff-Iversen S; Vangen S; Weiderpass E; Ursin G; Hofvind S
Int J Cancer; 2016 Feb; 138(3):584-93. PubMed ID: 26289549
[TBL] [Abstract][Full Text] [Related]
25. Hormone replacement therapy use and variations in the risk of breast cancer.
Opatrny L; Dell'Aniello S; Assouline S; Suissa S
BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
[TBL] [Abstract][Full Text] [Related]
26. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone.
Hanifi-Moghaddam P; Gielen SC; Kloosterboer HJ; De Gooyer ME; Sijbers AM; van Gool AJ; Smid M; Moorhouse M; van Wijk FH; Burger CW; Blok LJ
J Clin Endocrinol Metab; 2005 Feb; 90(2):973-83. PubMed ID: 15572424
[TBL] [Abstract][Full Text] [Related]
27. Endometrial effects of tibolone in elderly, osteoporotic women.
Ettinger B; Kenemans P; Johnson SR; Mol-Arts M; Van Os S; Seifert W; Verweij PJ; Cummings SR
Obstet Gynecol; 2008 Sep; 112(3):653-9. PubMed ID: 18757665
[TBL] [Abstract][Full Text] [Related]
28. [Reasons for abandonment of hormone replacement therapy with tibolone in menopausal women].
Zayas-Jaime FJ; Ornelas-Aguirre JM; Pérez-Nápoles DE
Ginecol Obstet Mex; 2013 Oct; 81(10):593-601. PubMed ID: 24483042
[TBL] [Abstract][Full Text] [Related]
29. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
30. Endometrial adenocarcinoma after prolonged tibolone therapy.
Nassar AH; Khalil AM; Seoud MA; Usta IM
Int J Gynaecol Obstet; 2005 Jul; 90(1):78-9. PubMed ID: 15913616
[No Abstract] [Full Text] [Related]
31. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
[TBL] [Abstract][Full Text] [Related]
32. [Clinical aspects of Livial in postmenopausal replacement therapy].
Grzechocińska B; Marianowski L
Ginekol Pol; 2002 Mar; 73(3):213-20. PubMed ID: 12092255
[TBL] [Abstract][Full Text] [Related]
33. Transvaginal ultrasonographic assessment of the endometrium in asymptomatic, postmenopausal women using different HRT regimens containing tibolone or estrogen.
Kurtay G; Berker B; Demirel C
J Reprod Med; 2004 Nov; 49(11):893-8. PubMed ID: 15603100
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis in the endometrium of postmenopausal women receiving tibolone.
Gökaslan H; Oktem O; Durmuşoglu F; Eren F
Gynecol Obstet Invest; 2003; 56(3):124-7. PubMed ID: 14504425
[TBL] [Abstract][Full Text] [Related]
35. Hormone replacement therapy in women with past history of endometriosis.
Soliman NF; Hillard TC
Climacteric; 2006 Oct; 9(5):325-35. PubMed ID: 17000581
[TBL] [Abstract][Full Text] [Related]
36. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study.
Bakken K; Alsaker E; Eggen AE; Lund E
Int J Cancer; 2004 Oct; 112(1):130-4. PubMed ID: 15305384
[TBL] [Abstract][Full Text] [Related]
37. A prospective study of postmenopausal hormone use and ovarian cancer risk.
Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
[TBL] [Abstract][Full Text] [Related]
38. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Kenemans P; Speroff L;
Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
[TBL] [Abstract][Full Text] [Related]
39. Cognitive effects of 10 years of hormone-replacement therapy with tibolone.
Fluck E; File SE; Rymer J
J Clin Psychopharmacol; 2002 Feb; 22(1):62-7. PubMed ID: 11799344
[TBL] [Abstract][Full Text] [Related]
40. Molecular analysis of human endometrium: short-term tibolone signaling differs significantly from estrogen and estrogen + progestagen signaling.
Hanifi-Moghaddam P; Boers-Sijmons B; Klaassens AH; van Wijk FH; den Bakker MA; Ott MC; Shipley GL; Verheul HA; Kloosterboer HJ; Burger CW; Blok LJ
J Mol Med (Berl); 2007 May; 85(5):471-80. PubMed ID: 17226044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
